Structure-Based Design of Novel Thiazolone[3,2-]pyrimidine Derivatives as Potent RNase H Inhibitors for HIV Therapy.

Ribonuclease H (RNase H) was identified as an important target for HIV therapy. Currently, no RNase H inhibitors have reached clinical status. Herein, a series of novel thiazolone[3,2-]pyrimidine-containing RNase H inhibitors were developed, based on the hit compound , identified from screening our in-house compound library. Some of these derivatives exhibited low micromolar inhibitory activity. Among them, compound was identified as the most potent inhibitor of RNase H (IC = 2.98 μM). The experiment of magnesium ion coordination was performed to verify that this ligand could coordinate with magnesium ions, indicating its binding ability to the catalytic site of RNase H. Docking studies revealed the main interactions of this ligand with RNase H. A quantitative structure activity relationship (QSAR) was also conducted to disclose several predictive mathematic models. A molecular dynamics simulation was also conducted to determine the stability of the complex. Taken together, thiazolone[3,2-]pyrimidine can be regarded as a potential scaffold for the further development of RNase H inhibitors.